Keynote-365 cohort C: Pembrolizumab (pembro) plus enzalutamide (enza) in   abiraterone (abi)-pretreated patients (pts) with metastatic castrate   resistant prostate cancer (mCRPC).

Titel:: Keynote-365 cohort C: Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC).
Dokumenttyp:: Meeting Abstract
Autor(en):: Fong, Peter C. C.; Retz, Margitta; Drakaki, Alexandra; Massard, Christophe; Berry, William R.; Romano, Emanuela; De Bono, Johann S.; Feyerabend, Susan; Appleman, Leonard Joseph; Conter, Henry Jacob; Sridhar, Srikala S.; Shore, Neal D.; Linch, Mark David; Joshua, Anthony; Gurney, Howard; Wu, Haiyan; Schloss, Charles; Poehlein, Christian Heinrich; Yu, Evan Y.
Zeitschriftentitel:: J Clin Oncol
Jahr:: 2019
Band / Volume:: 37 Suppl S
Heft / Issue:: 7
Volltext / DOI:: doi:10.1200/JCO.2019.37.7_suppl.171
Print-ISSN:: 0732-183X
TUM Einrichtung:: Urologische Klinik und Poliklinik
BibTeX

Vorkommen: